1. "2012"
Formats
  1. Journal Article (2365)
  2. Meeting Abstract (1182)
  3. Book Section (137)
  4. Conference Paper (23)
  5. Book Whole (10)
  6. Correspondence (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (1284)
  2. Surgery (899)
  3. GSK Faculty (811)
  4. Solid Tumor Oncology Division (708)
  5. Survivorship Research (632)
  6. Sloan Kettering Institute Faculty (579)

More Groups

People
  1. Clifford Hudis (64)
  2. Nancy Lee (64)
  3. Sergio Giralt (59)
  4. Robert Motzer (57)
  5. Richard Barakat (54)
  6. Howard Scher (53)

More People

Years
  1. 2012 (3719)
Publications
  1. Journal of Clinical Oncology (315)
  2. Blood (152)
  3. International Journal of Radiation Oncology, Biology, Physics (125)
  4. Cancer Research (110)
  5. Modern Pathology (80)
  6. Gynecologic Oncology (76)

More Publications

Publishers
  1. Elsevier Inc. (519)
  2. American Society of Clinical Oncology (337)
  3. Springer (239)
  4. Nature Publishing Group (202)
  5. Wiley Blackwell (193)
  6. American Association for Cancer Research (192)

More Publishers

Results (3719)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of Ifrt among pediatric patients with chemosensitive Hodgkin lymphoma: A subgroup analysis of the Cog Ahod 0031 study
    Meeting Abstract

    Charpentier, A. M.; Friedman, D. L.; Wolden, S.; Schwartz, C.; Albert-Green, A.; Kelly, K. M.; Constine, L.; Hodgson, D. C.
    Pediatric Blood and Cancer (2012)

    Fulltext@MSK | Save
  • A phase 2 randomized study of ramucirumab (IMC 1121B; RAM) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM) (CP12-0604/NCT00533702)
    Meeting Abstract

    Carvajal, R.; Thompson, J.; Gordon, M.; Lewis, K.; Pavlick, A.; Wolchok, J.; Rojas, P.; Schwartz, J.; Bedikian, A.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Role of repeat staging laparoscopy in locoregionally advanced gastric cancer after completion of neoadjuvant therapy
    Meeting Abstract

    Cardona, K.; Zou, Q. C.; Gonen, M.; Strong, V. E.; Brennan, M. F.; Coit, D. G.
    Annals of Surgical Oncology (2012)

    Fulltext@MSK | Save
  • Predicting outcome after hepatectomy for metastatic colorectal cancer: Is the answer in the primary tumor?
    Meeting Abstract

    Cardona, K.; D'amico, F.; Shia, J.; Gonen, M.; Weiser, M. R.; Paty, P. B.; Kingham, T. P.; Allen, P. J.; DeMatteo, R. P.; Fong, Y.; more...
    Annals of Surgical Oncology (2012)

    Fulltext@MSK | Save
  • Multiple testing methods for analyzing rare genetic variants
    Meeting Abstract

    Capanu, M.; Seshan, V.; Begg, C. B.
    Genetic Epidemiology (2012)

    Fulltext@MSK | Save
  • Risk of occult irresectable disease at liver resection for hepatic colorectal metastases: A contemporary analysis
    Meeting Abstract

    Bickenbach, K. A.; DeMatteo, R. P.; Fong, Y.; Kingham, P.; Allen, P. J.; Jarnagin, W. R.; D'Angelica, M. I.
    Annals of Surgical Oncology (2012)

    Fulltext@MSK | Save
  • The impact of abiraterone acetate (AA) therapy on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Basch, E.; Ryan, C. J.; Kheoh, T.; Fizazi, K.; Logothetis, C. J.; Rathkopf, D. E.; Smith, M. R.; Mainwaring, P. N.; Hao, Y.; Griffin, T.; more...
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Mifamurtide (L-MTP-PE) for metastatic and recurrent osteosarcoma (OS): Survival and safety profile from a patient access study
    Meeting Abstract

    Anderson, P.; Meyers, P.; Kleinerman, E.; Oliva, C.; Liu, Y.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • An evidence-based proposal of oncology-specific risk factors for morbidity and mortality after complex cancer surgery
    Meeting Abstract

    Aloia, T. A.; Cooper, A. B.; Strong, V. E.; Hoskins, W. J.; Sovel, M.; Shi, W.; Jordan, V. S.; Chang, G. J.; Skibber, J. M.; Lee, J. E.; more...
    Annals of Surgical Oncology (2012)

    Fulltext@MSK | Save
  • Updated overall survival analysis in oceans, a randomized phase 3 trail of gemcitabine (G) + carboplatin (C) and bevacizumab (BV) or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
    Meeting Abstract

    Aghajanian, C.; Nycum, L. R.; Goff, B.; Nguyen, H.; Husain, A.; Blank, S. V.
    Annals of Oncology (2012)

    Fulltext@MSK | Save